您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Voreloxin
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Voreloxin
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Voreloxin图片
CAS NO:175414-77-4
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品名称
SNS-595
Vosaroxin
AG 7352
产品介绍
Voreloxin (SNS-595; Vosaroxin; AG 7352) 是一种新创的拓扑异构酶 II (topoisomerase II) 抑制剂,能够诱导 DNA 双链断裂,阻滞 G2 期,最终细胞凋亡。
生物活性

Voreloxin (SNS-595; Vosaroxin; AG 7352) is a first-in-classtopoisomeraseIIinhibitor that intercalates DNA and induces site-selective DNA DSB, G2 arrest, andapoptosis.

IC50& Target

Topoisomerase II

 

体外研究
(In Vitro)

Voreloxin is a first-in-class topoisomerase II poison and inhibitor that intercalates DNA and induces site-selective DNA DSB, G2 arrest, and apoptosis. Voreloxin (0.1-20 μM) inhibits topoisomerase II activity and induces site-selective DNA DSB in CCRF-CEM cells. Voreloxin (0.11, 0.33, 1, 3 μM) induces G2 arrest partially through topoisomerase II in A549 lung cancer cell line. Voreloxin cytotoxic activity requires DNA intercalation. However, Voreloxin (1-9 μM) does not generate significant levels of ROS[1]. Voreloxin has potent cytotoxic activity in AML cell lines MV4-11 and HL-60, with IC50s of 95 ± 8 nM and 884 ± 114 nM, respectively. Voreloxin in combination with cytarabine shows additive or synergistic activity in acute leukemia cell lines[2]. Voreloxin is active on the primary acute myeloid leukemia (AML) with a mean LD50of 2.3 μM. The LD50for voreloxin in myeloid cell lines NB4 and HL-60 is 0.59 μM ± 0.25 μM. Voreloxin causes accumulation of cells in the S and G2 phases of the cell cycle and acts on topoisomerase II[3].

体内研究
(In Vivo)

Voreloxin (20 mg/kg, i.v.) alone results in 80% reduction in bone marrow cellularity of CD-1 mice by administration one dose every 4 days repeated twice (q4d ×2). voreloxin at 10 mg/kg in combination with cytarabine causes ablation of the marrow, dilation of sinusoids, and infiltration of adipocytes in mice. Voreloxin (20 mg/kg, i.v.) combined with cytarabine causes a reversible decrease in myeloid and lymphoid cells in bone marrow and peripheral blood CD-1 mice. voreloxin (10 mg/kg, q4d ×2) and cytarabine in combination causes reversible neutropenia with a more modest impact on platelets CD-1 mice[2].

Clinical Trial
分子量

401.44

Formula

C18H19N5O4S

CAS 号

175414-77-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.